AstraZeneca and Oracle have agreed to work together on one of drug development's most stubborn bottlenecks: finding the right patients for clinical trials and spotting people who need treatment earlier. The two companies announced the collaboration on Tuesday, October 20, 2026, with AstraZeneca contributing its scientific, clinical development and regulatory know-how and Oracle Health and Life Sciences providing real-world data, cloud infrastructure and AI-enabled clinical software.
The agreement is deliberately exploratory. Both companies describe it as a non-binding term sheet, they disclosed no financial terms, and the announcement lists areas to investigate rather than products or deadlines. Those areas are trial recruitment and matching, earlier diagnosis, monitoring of drug safety, guideline-directed care and the use of real-world evidence across a medicine's whole lifecycle. The disease focus follows AstraZeneca's main franchises: oncology, cardiovascular, renal and metabolic conditions, respiratory and immunology, and rare diseases.
The first concrete project is in the United Arab Emirates. Working with the Abu Dhabi healthcare company M42, the partners plan to help clinicians identify people whose high blood pressure is not under control, bring their treatment in line with clinical guidelines and improve enrolment in hypertension studies. AstraZeneca chief executive Pascal Soriot discussed the programme with CNBC at the Future Health Summit in Abu Dhabi. Later projects are expected in the United States, the Middle East and Europe, run with local governments and under each region's rules.
How the data is handled is central to the pitch. The companies say they will work only with de-identified real-world data, that AstraZeneca will not receive information that identifies patients, and that every proposed project will be reviewed on its own and will begin only once its legal, ethical, regulatory, institutional and privacy protections have been settled. Oracle adds that the partners intend to create joint oversight, build technical pieces that can be reused, agree on how outcomes will be measured, and use the results to judge whether an approach should be extended to other diseases or countries.
Executives on both sides framed the deal around speed. Soriot said it would help clinicians find patients sooner and produce evidence continuously throughout a medicine's life. Oracle chief executive Mike Sicilia called healthcare one of the most important areas for AI, and Seema Verma, who runs Oracle Health and Life Sciences, stressed that the work would happen under the governance of the health systems that deliver care.
The move fits a pattern. Fierce Biotech notes that AstraZeneca has already built Reinvent, an open-source generative AI framework for molecule design, and signed deals this year with Owkin and Evinova to speed up clinical development, while Oracle launched its Oracle Life Sciences AI Data Platform earlier in the year.
Because the agreement is non-binding, it commits neither company to a specific product, budget or timetable. Neither side has published targets or results for the Abu Dhabi programme, and whether AI-driven patient matching actually shortens recruitment will depend on data quality and on approval from regulators and health systems for each project.